30 07, 2024

Clinilabs Welcomes Michael Detke To The Clinilabs Scientific Advisory Board

2024-07-31T08:53:00-04:00July 30th, 2024|

Mike Detke, MD, PhD is a board-certified Psychiatrist, drug development scientist, and executive with over 25 years of research and leadership experience in the biotech and pharmaceutical sectors. Experienced across numerous CNS diseases and all phases of development, including many INDs and NDAs, he is a data-driven, high-integrity, transparent communicator and leader who always puts [...]

25 07, 2024

Join us as we welcome Paul Michael Ramirez PhD to Clinilabs Scientific Advisory Board

2024-07-30T10:40:39-04:00July 25th, 2024|

Rater training is crucial in clinical trials providing consistency and quality of subjective data collected from patients, caregivers, and clinicians, thereby ensuring the integrity of clinical trial endpoints and potentially leading to better clinical outcomes. Whereas poor management of rater training can have a detrimental effect on the entire study. Paul Michael Ramirez, PhD, is [...]

18 06, 2024

Join us as we welcome Justin Brooks, MD, PhD to Clinilabs Scientific Advisory Board

2024-06-18T11:06:55-04:00June 18th, 2024|

Justin Brooks, MD, PhD is a physician-engineer and scientist who currently serves as the Director of Strategic Initiatives at the University of Maryland Institute for Health Computing with his primary appointment as an Associate Professor of Computer Science and Electrical Engineering at UMBC. Clinilabs is thrilled to welcome Dr. Brooks to the team and eagerly [...]

17 06, 2024

Sandra Comer, PhD was recognized at CPDD 2024 with two distinguished awards.

2024-06-18T11:31:41-04:00June 17th, 2024|

Sandra Comer, PhD, has been honored with two awards from the College on Problems of Drug Dependence (CPDD) at this year's annual meeting. She was recognized for her exceptional contributions to the field of drug abuse. Dr. Comer received both the Martin and Toby Adler Distinguished Service Award as well as the Marian W. Fishman [...]

15 06, 2024

Harald Murck, MD joins Clinilabs as a Scientific Advisory Board Member

2024-06-15T12:30:30-04:00June 15th, 2024|

  Clinilabs is excited to announce that Harald Murck, MD has joined our Scientific Advisory Board. Professor Harald Murck, MD, brings with him over 20 years of experience working with small biotech and large pharmaceutical companies. He has overseen and made significant contributions to the development of compounds in psychiatric indications and is considered an [...]

12 06, 2024

Clinilabs celebrates our Scientific Advisory Board Member, Rashmi Patel, MD, PhD

2024-06-15T09:10:43-04:00June 12th, 2024|

Join us as we celebrate our Scientific Advisory Board Member, Rashmi Patel, MD, PhD, in his new endeavors as Clinical Assistant Professor in the Department of Psychiatry at the University of Cambridge.

11 06, 2024

Clinilabs supports centralized PSG data management and analysis during Idorsia’s clinical development of Daridorexant

2024-06-15T09:08:58-04:00June 11th, 2024|

"Hyperarousal Features in the Sleep Architecture of Individuals with and without Insomnia," analyzed data from 1,710 individuals with insomnia and 1,455 individuals without insomnia. It found that individuals with insomnia showed signs of hyperarousal, including higher likelihood of waking from all sleep stages, increased relative alpha and theta power during certain sleep stages, decreased relative [...]

5 06, 2024

Featured at SLEEP2024 Lemborexant Effect on Sleep Parameters in Adults With Moderate or Severe Chronic Obstructive Pulmonary Disease

2024-06-15T09:16:20-04:00June 5th, 2024|

Eisai and Clinilabs Drug Development Corporation conducted an analysis of Lemborexant (LEM) to determine its effectiveness as a treatment for insomnia. LEM is a competitive dual orexin-receptor antagonist that has been approved in multiple countries for the treatment of insomnia in adults. The analysis found that LEM helps improve sleep duration, daytime functioning, and fatigue [...]

31 05, 2024

Featured at ASCP “Effects of Lemborexant on Sleep Architecture in Adults and Elderly Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease”

2024-06-15T09:13:21-04:00May 31st, 2024|

Gary Zammit, President and CEO of Clinilabs Drug Development Corporation, was at the ASCP conference in Miami Beach in May, where Dr. Zammit and the team at Eisai Inc. discussed the "Effect of Lemborexant on Sleep Architecture in Adults and Elderly Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease," presented on Poster #59.

Go to Top